top of page

helIcObacter P.ylOrI
Helicobacter pylori is a bacterium that colonises the protective mucus layer lining the stomach. Once established, it triggers a persistent low-grade inflammatory response. This chronic inflammation damages the stomach’s protective systems and exposes underlying nerve endings to acid and digestive enzymes, which produces epigastric pain and burning. The inflammation can also interferes with normal gastric motility and accommodation, leading to delayed emptying, bloating, nausea, and early satiety.
Helicobacter pylori also alters acid regulation and which can either increase or decrease gastric acid secretion depending on the pattern and location of the infection. This can promote reflux of acidic contents into the esophagus, resulting in heartburn and esophageal irritation.
Furthermore, in order for Helicobacter pylori to survive the normally highly acidic stomach environment, H. pylori produces urease, an enzyme that converts urea into ammonia, locally neutralising stomach acid and creating a more favourable environment for bacterial persistence. By suppressing this acid-producing machinery, the bacterium effectively reduces overall stomach acid output, contributing to hypochlorhydria. This reduction in acid alters digestion, impairs antimicrobial defence, and promotes further microbial imbalance, reinforcing chronic inflammation and ongoing gastric dysfunction. [27]
signs & symptoms
Stomach Ulcers / Peptic Ulcers
-
Upper abdominal burning or gnawing pain
Helicobacter pylori is responsible for up to 90% of gastric ulcers. [30] This is because Helicobacter pylori produces urease, generating ammonia that injures epithelial cells, disrupts mucus integrity, and triggers an inflammatory immune response with cytokines such as IL-8, leading to ongoing mucosal injury. Infection of the antrum increases gastrin and reduces somatostatin, resulting in excess acid secretion that further exacerbates tissue damage. Together, inflammation, impaired mucosal defense, and increased acid exposure culminate in gastric ulcer formation.
Gastritis
-
Epigastric or upper abdominal pain
-
Dyspepsia - indigestion, early satiety, bloating
-
Nausea
-
Vomiting
-
Gastric discomfort related to meals
The inflammatory responses related to H.Pylori infection cause inflammation of the stomach lining - Gastritis. The inflammatory cytokines such as IL-8 that are released, damage the protective mucus layer, exposing sensory nerve endings to gastric acid and pepsin, which generates epigastric pain and burning discomfort. Furthermore the mucosal irritation and swelling also impair normal gastric motility and accommodation, contributing to early satiety, bloating, nausea, and vomiting. In addition, inflammation alters acid secretion and disrupts digestive signaling, leading to symptoms of dyspepsia. [28]
Reflux + GERD
-
Heartburn
-
Esophageal Irritation
-
Regurgitation
The relationship between Helicobacter pylori infection and gastroesophageal reflux disease (GERD) is complex and not causally linear. H. pylori alters gastric physiology through chronic inflammation, disrupting the balance between somatostatin and gastrin, which can either increase or decrease gastric acid secretion depending on the pattern and location of gastritis. In antral-predominant infection, increased gastrin can raise acid output and potentially exacerbate reflux. [29]
It is important to note that eradication of H. pylori restores acid secretion, which can worsen reflux symptoms in patients with other pre-existing GERD risk factors such as hiatal hernia, obesity, or impaired lower esophageal sphincter function.
Yellow Tongue Coating
H. pylori alters gastric acid secretion, digestive efficiency, and bile handling, which promote oral dysbiosis and accumulation of chromogenic bacteria on the dorsal tongue surface. Reduced gastric acidity and delayed gastric emptying may allow reflux of bile acids and bacterial metabolites into the upper gastrointestinal tract and oral cavity, contributing to a yellow discoloration on the tongue.
In one study, approximately 81% of H. pylori–positive patients presented with a yellow tongue coating, whereas H. pylori negative cases most often showed white or white-to-pale yellow coatings. This suggests that tongue appearance may serve as a simple, non-invasive marker that correlates with underlying infection and gastric dysfunction, and should be noted when identified [31].
GI Infections and Digestive Complaints
-
Bloating
-
Gas
-
Abdominal Discomfort
Helicobacter pylori infection can have broad downstream effects on digestion by disrupting the stomach’s role as a primary digestive and antimicrobial barrier. By reducing gastric acid secretion, H. pylori impairs protein digestion and diminishes the stomach’s ability to sterilise ingested food. Low stomach acid allows survival and overgrowth of pathogenic and opportunistic microorganisms in the upper gastrointestinal tract, increasing susceptibility to secondary GI infections and bacterial overgrowths. In addition, impaired gastric emptying and altered digestive signalling promote fermentation of poorly digested food substrates, leading to bloating, gas and abdominal discomfort.
Causes
Exposure
Helicobacter pylori is typically contracted through person-to-person transmission involving contaminated oral or gastrointestinal secretions.
Common transmission routes
-
Ingestion of food or water contaminated with fecal matter containing H. pylori
-
Transmission via saliva, shared utensils, cups, or poor oral hygiene
-
Exposure to vomitus or gastric secretions, particularly in household or caregiving settings
Hypochlorhydria - Low Stomach Acid
Low gastric acid states facilitate more extensive Helicobacter pylori colonisation by reducing one of the stomach’s primary innate defence mechanisms, thereby allowing the organism to persist beyond its usual, and extend into the gastric corpus, a region typically protected by higher acid output. Clinically, corpus colonisation is associated with stomach inflammation (gastritis), parietal cell impairment, and an increased risk of carcinoma. Thus, low stomach acid does not merely permit H. pylori survival, but actively enables broader gastric colonisation.
Whereas under normal acidic conditions, most ingested bacteria are rapidly killed or flushed into the intestine; however, when gastric acidity is reduced, H. pylori is less likely to be eliminated during early exposure and can more effectively adhere to the gastric mucosa. [44]
Since there are various conditions that lower stomach acid production, eradication and recurrence prevention requires a holistic approach, treating any of the following:
Dysbiosis + Gastric Inflammation
Dysbiosis is characterized by an imbalance in the gastric microbiota with increased populations of bacteria such as Streptococcus, Prevotella, and Haemophilus. Dysbiosis, in turn, contributes to chronic low-grade inflammation through the activation of immune pathways leading to the release of inflammatory cytokines such as TNF-alpha, IL-1, IL-6. These cytokines cause mucosal damage and contribute to the destruction of gastric epithelial cells, including parietal cells, affecting their ability to secrete gastric acid. [38]
Small Intestinal Bacterial Overgrowth (SIBO)
An overgrowth of bacteria in the small intestine, creates a chronic increase in the production of alkaline gases such as ammonia and methane, as a byproduct of metabolism. As alkaline substances these gases have the capacity to neutralise gastric acid, leading to a chronic reduction in acidity. [36][37]
High Sugar Intake
D-cells in the stomach produce a hormone known as Somatostatin in response to elevated blood sugar levels. Somatostatin works to inhibit stomach acid production by decreasing the release of gastrin, histamine, and directly inhibiting the parietal cells, thus reducing acid secretion.[35]
Chronic Stress [ SNS Hyperactivity ]
Moderate levels of stress increase nitric oxide synthesis, and this causes inhibition of gastric acid secretion. [33]
Medications
Long-term use of the following medications suppress stomach acid production via their mechanism of action:
Proton Pump Inhibitors (PPIs) - block the gastric proton pump to strongly suppress acid production
-
Nexium
-
Somac
-
Losec
H₂ Receptor Antagonists - block histamine receptors in the stomach, reducing acid
-
Pepzan, Pepcid
-
Tazac
Antacids – neutralise existing stomach acid to provide quick, short-term relief
-
Quick-Eze, Rennie
-
Mylanta, Gaviscon Dual Action
-
Sodium bicarbonate
Autoimmune Gastritis
Autoimmune gastritis is where the body’s immune system attacks the stomach lining, particularly the parietal cells that produce hydrochloric acid. Over time, this immune damage reduces stomach acid levels long-term. [34]
Age
Similarly, the elderly show relatively low stomach acidity. According to a report on 1590 patients, the incidence of low stomach acid was 19% in the fifth decade of life and 69% in the eighth decade of life. [32]
References
[27] https://pmc.ncbi.nlm.nih.gov/articles/PMC8544542/
[28] https://www.ncbi.nlm.nih.gov/books/NBK534233/
[29] https://pmc.ncbi.nlm.nih.gov/articles/PMC6502218/
[30] https://www.ncbi.nlm.nih.gov/books/NBK534792/
[31] https://www.researchgate.net/publication/283716892
[32] https://emedicine.medscape.com/article/170066-overview?form=fpf#a6
[33] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26223/
[34].https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.906122/full
[35].https://www.sciencedirect.com/topics/medicine-and-dentistry/somatostatin-release
[36] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531573/
[37] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609274/
[38] https://pmc.ncbi.nlm.nih.gov/articles/PMC4616220/
[39] https://pmc.ncbi.nlm.nih.gov/articles/PMC3623263/
[40] https://pmc.ncbi.nlm.nih.gov/articles/PMC4725184/
[41] https://pmc.ncbi.nlm.nih.gov/articles/PMC5233496/
[42] https://pmc.ncbi.nlm.nih.gov/articles/PMC10136991/
[43] https://pmc.ncbi.nlm.nih.gov/articles/PMC4725184/
[44] https://pubmed.ncbi.nlm.nih.gov/28124156/
[45] https://pmc.ncbi.nlm.nih.gov/articles/PMC5052411/
[46] https://academic.oup.com/femspd/article/50/2/231/682532
[47] https://pmc.ncbi.nlm.nih.gov/articles/PMC2694061/
[48] https://europepmc.org/article/MED/31380260
[49] https://www.bmj.com/content/bmj/326/7392/737.1.abridgement.pdf
[50].https://www.sciencedirect.com/science/article/abs/pii/S0140673620304694
[51] https://pmc.ncbi.nlm.nih.gov/articles/PMC8719756/
[52] https://pmc.ncbi.nlm.nih.gov/articles/PMC9914867/

bottom of page